Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy

Ph II CABOGIST in GIST

NCT02216578 ·Status: COMPLETED ·Phase: PHASE2

Lenvatinib After Progression on Imatinib, Sunitinib, and Regorafenib for GIST Patients

NCT07096609 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

A Phase I/II Study of Sunitinib Malate (SU011248) In Patients With Gastrointestinal Stromal Tumor (GIST)

NCT00457743 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

A Treatment Protocol for Patients With Gastrointestinal Stromal Tumor (GIST) Who May Derive Benefit From Treatment With SU011248

NCT00094029 ·Status: APPROVED_FOR_MARKETING

A Clinical Study of Regorafenib in Participants Who Have Been Treated in Previous Bayer-sponsored Regorafenib Studies That Have Been Completed

NCT03890731 ·Status: COMPLETED ·Phase: PHASE2

A Study of Continued Treatment With Regorafenib in Participants With Solid Tumors Who Have Participated in Other Bayer Studies

NCT06246643 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma

NCT03410693 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor

NCT01396148 ·Status: COMPLETED ·Phase: PHASE2

Pharmacokinetics and Safety of Regorafenib (BAY73-4506) in Cancer Subjects With Severe Renal Impairment

NCT01853046 ·Status: COMPLETED ·Phase: PHASE1

Non-Interventional Retrospective Correlation Of Tumor Mutational Status To Clinical Benefit Of GIST Patients Treated With Sunitinib

NCT01459757 ·Status: COMPLETED

Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib Malate

NCT00265798 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Regorafenib Phase I Study in Mainland Chinese Patients

NCT02398513 ·Status: COMPLETED ·Phase: PHASE1

A Study Evaluating STA-9090 in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor (GIST)

NCT01039519 ·Status: COMPLETED ·Phase: PHASE2

Apatinib Mesylate Versus Standard Second-line TKI in the Treatment of Advanced GIST

NCT05751733 ·Status: RECRUITING ·Phase: NA

A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib

NCT03673501 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

A Phase 2 Study of XL820 in Adults With Advanced GIST Resistant to Imatinib and/or Sunitinib

NCT00570635 ·Status: COMPLETED ·Phase: PHASE2

Study Of SU011248 Administered On A Continuous Daily Dosing Schedule In Patients With Gastrointestinal Stromal Tumor

NCT00137449 ·Status: COMPLETED ·Phase: PHASE2

Single Agent Regorafenib in Refractory Advanced Biliary Cancers

NCT02115542 ·Status: COMPLETED ·Phase: PHASE2

A Study of Sunitinib Versus Placebo in Combination With Lanreotide in Patients With Progressive Advanced/Metastatic Midgut Carcinoid Tumors

NCT01731925 ·Status: UNKNOWN ·Phase: PHASE2

Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors

NCT02259725 ·Status: COMPLETED ·Phase: PHASE2

A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy

NCT07218926 ·Status: RECRUITING ·Phase: PHASE3

Expanded Access to Bezuclastinib to be Coadministered With Sunitinib for Patients With Gastrointestinal Stromal Tumors

NCT06948955 ·Status: AVAILABLE

Kinase Genotyping of Gastro Intestinal Stomach Tumors (GISTs) From Patients Enrolled in Pfizer A6181112 Phase IIIb Trial

NCT00640692 ·Status: WITHDRAWN

Sunitinib in Patients With Advanced Gastric Cancer and Treated With FOLFIRI

NCT01020630 ·Status: COMPLETED ·Phase: PHASE2

Efficacy and Safety of Sunitinib in Metastatic Gastric Cancer

NCT00411151 ·Status: COMPLETED ·Phase: PHASE2